Navigation Links
New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma Receiving R-CHOP Chemotherapy
Date:6/13/2010

g pharmaceutical pricing and reimbursement.  Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products.  In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products.  We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products.  In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates.  We cannot guarantee that we will be able to produce commercially successful products or maintain the commercial success of our existing products.  Our stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of our products or product candidates.  Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations.

The scientific information discussed in this news release related to our product candidates is preliminary and investigative.  Such product candidates are not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates.  Only the FDA c
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Watson Confirms Renvela® Patent Challenge
2. China Sky One Medical Confirms Continued Sale of Seven of Eight Products on the Ministry of Healths Warning List
3. Publication in Neuropsychopharmacology Confirms CeNeRxs Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A
4. Vivakor Confirms Record Date of Stock Dividend
5. New study confirms exotic electric properties of graphene
6. Monsanto Reconfirms 2010 Guidance and 2012 Financial Commitments on Strength of Larger Expected Launches for Blockbuster Products
7. Analysis confirms that nano-related research has strong multidisciplinary roots
8. ImmuneRegen BioSciences Confirms Homsperas Therapeutic Anti-Influenza Effect on Pandemic H1N1 Influenza Virus After Oral Administration
9. Independent Study Confirms Superior Properties of ZPC(TM) Enhanced Calcium Composite Bone Grafts
10. Independent U.S. Study Confirms Veritides Ceeker(TM) Handheld Device Detects Anthrax With Outstanding Accuracy and Reliability
11. Dow AgroSciences Confirms Efficacy of Zinc Finger Nucleases for Precise Genome Modification in Maize
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)...  A novel biomarker for rheumatoid arthritis (RA) ... early-stage disease, when treatment can often arrest further ... study in The Journal of Rheumatology. ... ) and other institutions found that elevated blood-serum ... testing, including rheumatoid factor (RF) and anti-citrullinated peptide ...
(Date:8/27/2014)... August 27, 2014 “We are honored ... vendors,” said Ven Thangaraj, CEO of Radiant Sage. “We ... are taking the imaging corelab market to a different ... and research organizations to efficiently and effectively manage the ... data to be analyzed and read by trained physicians. ...
(Date:8/27/2014)... , Aug. 27, 2014 Guggenheim Securities, ... Partners, today announced the hiring of veteran equity analyst ... equity analyst. Mr. Butler will focus on the biotech/biopharma ... team a wealth of experience and a broad network ... , Senior Managing Director and Head of Equities at ...
(Date:8/27/2014)... 2014 Reportbuyer.com has added a new ... - A Rational View https://www.reportbuyer.com/product/1595336/The-Graphene-Opportunity---A-Rational-View.html ... A similar amount of hype currently surrounds ... microelectronics to water treatment, but is graphene the ... the Graphene Opportunity Report, authored by Tim ...
Breaking Biology Technology:Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 2Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 3Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 4Radiant Sage Named to CIOReview List of 100 Most Promising Technology Companies 2Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2The Graphene Opportunity - A Rational View 2The Graphene Opportunity - A Rational View 3The Graphene Opportunity - A Rational View 4
... ANGELES, Oct. 20 The Cure Our Children ... today,that the U.S. Food and Drug Administration (FDA) ... unique drug product for children with,Ewing,s Sarcoma cancer. ... possible,by the generous volunteers and researchers in private ...
... Oct. 20 On Wednesday, October,22, 2008, GlaxoSmithKline plc ... results for the three months ended September 30, 2008. ... Exchange at,approximately 12:00pm UK, 7:00 am EDT., At ... global teleconference,for analysts and investors, hosted by Andrew Witty, ...
... Oct. 20 Sustainable Oils has named ... as the company,s general manager. Scott Johnson ... to build camelina,production and marketing opportunities for ... joined the company on Oct. 1., ...
Cached Biology Technology:FDA Approves Orphan Drug Status for Revolutionary Cancer Drug for Children 2Sustainable Oils Names Scott Johnson as General Manager, Expands Management Team for Camelina Research and Production 2Sustainable Oils Names Scott Johnson as General Manager, Expands Management Team for Camelina Research and Production 3Sustainable Oils Names Scott Johnson as General Manager, Expands Management Team for Camelina Research and Production 4
(Date:8/27/2014)... /PRNewswire-iReach/ -- The IEEE Engineering in Medicine and Biology ... International Conference (EMBC,14), this year being held at the ... Illinois , from Tuesday, August 26 through Saturday, ... industry professionals in science, medicine, and engineering are registered ... This year,s conference theme is ...
(Date:8/27/2014)... as giant, frightening beasts. But every creature is a ... slab containing fossils of 24 very young dinosaurs and ... hatchlings overseen by a caretaker, according to a new ... P. Hedrick and Peter Dodson led the work, collaborating ... where the specimen is held. Hedrick is a doctoral ...
(Date:8/27/2014)... is available in German . ... the most common inherited disease affecting the peripheral nervous ... Max Planck Institute of Experimental Medicine and University Medical ... cells is impaired in rats with the disease. These ... known as myelin, which facilitates the rapid transfer of ...
Breaking Biology News(10 mins):Global Leaders In Science, Medicine, And Engineering Gather For The 36th Annual International Conference Of The IEEE Engineering In Medicine And Biology Society, August 26-30 In Chicago 2Global Leaders In Science, Medicine, And Engineering Gather For The 36th Annual International Conference Of The IEEE Engineering In Medicine And Biology Society, August 26-30 In Chicago 3Penn paleontologists describe a possible dinosaur nest and young 'babysitter' 2Penn paleontologists describe a possible dinosaur nest and young 'babysitter' 3Potential therapy for incurable Charcot-Marie-Tooth disease 2
... the first human clinical trial of a recombinant vaccine ... ?and the results indicate the vaccine is safe and ... Center researchers report. , The nearly year-long pilot study ... each group received a series of three injections of ...
... Medical Center have uncovered part of the genetic mechanism that ... , A team led by SFVAMC vascular surgeon Rajabrata Sarkar, ... is essential for the growth of new arteries when the ... identified and described, for the first time, the specific DNA ...
... Brookhaven National Laboratory have just launched a web-based 3-D ... a popular laboratory mouse (see http://www.bnl.gov/CTN/mouse/ ). ... extremely accurate anatomical templates and use them to map ... brain are metabolically active and where particular genes are ...
Cached Biology News:Human trial proves ricin vaccine safe, induces neutralizing antibodies; further tests planned 2Human trial proves ricin vaccine safe, induces neutralizing antibodies; further tests planned 3Human trial proves ricin vaccine safe, induces neutralizing antibodies; further tests planned 4Genetic key to growth of new arteries is identified 2Genetic key to growth of new arteries is identified 3
ANTI S. ENT TOX BC2D...
Porcine Serum US Origin 6 Months or Older...
... PlusOne Silver Staining Kit, Protein, ... Heukeshoven and Dernick (1), the kit ... gel electrophoresis systems.Silver Staining Kit, Protein ... of proteins in polyacrylamide gels in ...
All serum is collected from adult animals aged 6 months or older. Certified U.S. orgin. Pricing: $35/unit for 1 - 10 units...
Biology Products: